类器官市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)

在预测期内，类器官市场预计将以 17.1% 的复合年增长率增长。

COVID-19 大流行对类器官市场产生了重大影响。 在有限的时间内推出 COVID-19 疫苗的研发活动增加，导致在大流行期间更多地采用类器官。 与真实器官的相似性、细胞嗜性和细胞活力是导致大流行期间类器官在药物开发中被高度采用的主要因素。 例如，在美国国家生物技术信息中心 (NCBI) 于 2022 年 2 月发表的一篇论文中，类器官可以通过提供适当的细胞异质性、病毒易感性和适当的宿主细胞反应来帮助研究 COVID-19。据报导，它们提供了极快的速度。 此外，据报导某些类器官可有效识别 COVID-19 的治疗方法。 例如，Springer Nature Limited 于 2021 年 5 月发表的一篇论文报告说，肺类器官在大流行期间检测 SARS-COV-2 病毒的治疗方案时显示出可喜的结果。

此外，在 Springer Nature Limited 于 2022 年 4 月出版的一份研究期刊中，人类多能干细胞衍生的气道类器官证明了 SARS-COV-2 病毒的特异性和病毒的传播能力。报告了评估选项的有效性减少 因此，在大流行期间，类器官在研究领域的使用增加，推动了市场增长。 然而，在大流行后的情况下，使用类器官的调查和临床试验显着增加。 例如，根据 ClinicalTrials.gov 的数据，从 2021 年 3 月 1 日到 2023 年 1 月 3 日，总共报告了 47 项涉及类器官的研究。 此外，MDPI 在 2022 年 6 月发表的一篇题为“3D Human Organoids: The Next"Viral"Model for the Molecular Basis of Infectious Diseases”的论文中指出，类器官可用于治疗 COVID-19、HIV、It已在乙型肝炎和丙型肝炎等多种疾病的调查中被证明有效，并在大流行后情况下的传染病研究中获得支持。 预计上述因素将有助于预测期内市场的进一步增长。 推动市场增长的因素包括慢性病患病率上升、基于类器官药物开发的研究数量增加以及类器官开发技术进步。

慢性病（包括心血管疾病、慢性肾病和癌症）的患病率在世界范围内呈上升趋势。 例如，2021 年 5 月国民健康服务 (NHS) 的一篇文章报导称，估计 2021 年英国将有 140 万人患有心房颤动。 此外，2021 年发表在 Annals of Cancer Epidemiology 上的一篇研究文章报告称，2021 年美国估计有 235,760 名新确诊肺癌患者。 患有许多慢性病的患者人数不断增加，这增加了医疗保健的负担，反过来又刺激了研发工作，以引入用于治疗这些慢性病的新药。我来了。 此外，越来越多地采用类器官模型进行研究和开发，以更好地了解疾病状态和药物对真实器官的影响。 据 ClinicalTrial.gov 称，这项名为“肠道类器官 (BIOIDES)”的研究于 2022 年 9 月在法国开始，将在使用潜在的胃肠道疾病治疗分子进行测试之前，以具有相关健康数据的消化器官为目标。我们的目标是开发一个生物集合来自活组织检查的类器官。

此外，在开发类器官及其在各种适应症（例如肺癌、基因改变、慢性肾病、心血管疾病和结肠癌）中的应用方面，药物研发方面的举措越来越多。主要观察者公司。 这些努力也推动了研究中对类器官的需求。 例如，根据 ClinicalTrials.gov 的数据，到 2022 年 12 月 31 日，共有 79 项针对类器官的临床研究。 除此之外，类器官模型开发的最新技术进步正在进一步提高类器官在药物研究中的性能。 例如，2022 年 10 月，AIM Biotech Pte. Ltd. 宣布了 organiX 系统。 该系统可以赋予类器官血管生成和免疫能力，并可以在研究过程中提高类器官的保质期。

由于药物研究领域对类器官的需求和采用不断增加，上述因素促进了市场的增长。 然而，类器官与真实器官之间的功能差异等临床缺点限制了类器官在调查期间的采用率。

类器官市场趋势

市场细分 按产品类型划分，药物发现和个性化医疗领域预计在研究期间将占据很大的市场份额。

慢性病患病率的增加以及大公司越来越多地向市场推出重磅药物的举措是在药物发现中越来越多地采用类器官等先进技术的主要原因。我来了。 例如，2022 年 8 月，Bayer AG推出了 finerenone 用于治疗慢性肾病。 此外，美国国家生物技术信息中心 (NCBI) 于 2022 年 5 月发表的一项研究报告称，患者来源的胰腺癌类器官在胰腺癌的药物发现中被证明是有效的。 与此同时，个性化医疗的兴起也推动了类器官在研究行业的采用率。

例如，个性化医疗联盟预测，到 2022 年，美国市场上将共有 300 种个性化医疗。 个性化医疗联盟的另一份报告称，到 2021 年，美国食品和药物管理局 (FDA) 批准的所有药物中约有 35% 将用于个性化医疗。 此外，根据 2021 年 Alix Ventures 的一份报告，由于某些因素（例如可追溯性和捕获患者和肿瘤类型多样性的潜力），类器官越来越多地用于个性化医学研究。支持类器官在生物医学发展中的需求和采用。 此外，某些临床优势，例如捕捉患者和肿瘤类型多样性的潜力以及细胞组成的保存，正在推动类器官在个性化医学研究中的采用。 例如，到 2022 年 12 月 31 日，ClinicalTrial.gov 报告了 31 项基于患者来源的类器官的临床试验。

因此，由于上述因素，药物发现和个性化医疗领域有望在研究期间获得显着的市场份额。

北美在预测期内贡献了最大的市场份额

在研究期间，预计北美地区将在全球类器官市场占据主导地位。 大量患有慢性病的患者、先进的医疗设施、主要参与者的存在以及联邦政府在该地区增加的研发支出是该地区市场增长的驱动因素。 根据美国疾病控制与预防中心（CDC）的数据，2022年美国共有2010万20岁及以上的成年人患有冠心病。 据美国肝臟基金会估计，2021 年美国将有 42,230 例肝癌新发病例。 此外，国家生物技术信息中心 2022 年 5 月发布的估计表明，2022 年加拿大将报告约 233,900 例新癌症病例。 此外，该地区还报导了一些涉及类器官的慢性疾病的临床试验。 根据 ClinicalTrial.gov 的数据，该试验于 2018 年 8 月在德克萨斯州开始，名为“用于肺癌治疗反应的患者衍生类器官模型和循环肿瘤细胞”，预计将于 2024 年 12 月完成。 本研究旨在建立一个用于肺癌治疗的患者来源类器官生物库，并研究潜在类器官对多种化疗药物的体外反应。 此外，北美不断增加的医疗保健研究支出正在推动先进技术在研究中的采用。 根据 2022 年 12 月美国政府问责办公室 (GAO) 的一份研究报告，美国联邦政府已将卫生与公共服务部的研发资金从 2020 年的 600 亿美元增加到 2021 年的 688 亿美元。

此外，美国政府的持续监管和现代化法律正在限制在药物临床试验中使用动物试验。 这导致在临床试验和其他药物开发程序中采用替代方法来测试药物。 出于这个原因，类器官在研究过程中的采用正在增加。

2022 年 FDA 现代化法案将消除在开发任何人类药物时进行动物试验的需要。 因此，由于上述因素，预计在预测期内，北美的类器官□□市场将持续增长。

类器官行业概览

类器官市场是整合的，由几个主要参与者组成。 就市场份额而言，目前少数大公司占据市场主导地位。 其中包括 Cellsce Ltd、Merck KGaA、3Dnamics Inc.、R&D Systems, Inc.、Hubrecht Organoid Technology、Definigen、Known Medicine 和 Dynomics Inc。

其他福利：

• Excel 格式的市场预测 (ME) 表
• 3 个月的分析师支持

内容

第一章介绍

• 研究假设和市场定义
• 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

• 市场概览
• 市场驱动力
  • 启动研发活动
  • 最新的类器官情况
• 市场製约因素
  • 区别于实际器官的特征
• 波特的五力分析
  • 新进入者的威胁
  • 买家/消费者的议价能力
  • 供应商的议价能力
  • 替代品的威胁
  • 竞争对手之间的竞争强度

第 5 章市场细分（按价值划分的市场规模）

• 按产品类型
  • 肠道
  • 肝臟
  • 胃
  • 胰腺
  • 其他
• 通过申请
  • 药物发现和个性化医疗
  • 药物的毒性和功效测试
  • 再生医学
  • 发育生物学
  • 其他
• 最终用户
  • 製药和生物技术公司
  • 委託研究机构
  • 关于研究机构
• 地区
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 韩国
    • 其他亚太地区
  • 中东和非洲
    • 海湾合作委员会
    • 南非
    • 其他中东和非洲地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲

第六章竞争格局

• 公司简介
  • Merck KGaA
  • Cellesce Ltd
  • 3Dnamics Inc.
  • R&D Systems, Inc.
  • Hubrecht Organoid Technology
  • Definigen
  • Known Medicine
  • Dynomics Inc.

第七章市场机会与未来趋势

The Organoids Market is projected to register a CAGR of 17.1% during the forecast period.

The COVID-19 pandemic had a significant impact on the organoids market. The increasing number of research and development activities for the introduction of the COVID-19 vaccine within a very limited time resulted in the higher adoption of organoids during the pandemic. The resemblance with actual organs, cell tropism, cell viability, and others are some of the key factors for the significant adoption of organoids during drug development at the time of the pandemic. For instance, an article published by the National Center for Biotechnology Information (NCBI) in February 2022, reported that organoids offered a significant pace in the research of COVID-19 by offering proper cellular heterogeneity, viral susceptibility, and appropriate host cell responses. Additionally, specific organoids were reported to be effective while identifying the treatment option for COVID-19. For instance, an article published by Springer Nature Limited in May 2021, reported that lung organoids had shown promising results while detecting the treatment options for the SARS-COV-2 virus during the pandemic.

Moreover, a research journal published by Springer Nature Limited in April 2022, reported that human pluripotent stem cell-derived airway organoids have shown certain specific characteristics of the SARS-COV-2 virus as well showed effectiveness while evaluating the options to limit the spread of the virus. This results in the increased use of organoids in the research field during the pandemic and fosters the market's growth. However, in the post-pandemic situation, the research studies and clinical trials increased significantly involving organoids. For instance, according to ClinicalTrials.gov, a total of 47 studies were reported involving organoids from 1st March 2021 till 3rd January 2023. Also, an article published by MDPI in June 2022, titled "3D Human Organoids: The Next "Viral" Model for the Molecular Basis of Infectious Diseases," reported that organoids were proven to be efficacious in the research of a number of disorders, including COVID-19, HIV, Hepatitis B, Hepatitis C among others and gained its traction in the research of infectious disease in the post-pandemic situation. The above-mentioned factors are anticipated to contribute to the further growth of the market during the forecast period.

There are certain factors that are driving the market growth, including the rising prevalence of chronic diseases, the rising number of research on drug development involving organoids, and technological advancements in the development of organoids. The prevalence of chronic diseases, including cardiovascular disease, chronic kidney disease, and cancer, among others, is increasing globally. For instance, according to an article by the National Health Service (NHS) in May 2021, it was reported that an estimated 1.4 million people in the United Kingdom were suffering from atrial fibrillation in 2021. Additionally, according to a research article published by the Annals of Cancer Epidemiology in 2021, an estimated 235,760 new lung cancer cases were diagnosed in the United States in 2021. This rising number of patients suffering from a number of chronic diseases is increasing the healthcare burden and, alternatively, increasing the research and development initiatives for the introduction of novel drugs to be used in these chronic diseases. Additionally, owing to a better understanding of the disease condition and the effect of drugs on the actual organs, the adoption of organoid models is increasing for R&D purposes. According to ClinicalTrial.gov, a study titled "Intestinal Organoids (BIOIDES)" started in September 2022 in France was aimed to develop a bio-collection of organoids from digestive biopsies with associated health data prior to testing them with potential therapeutic molecules for gastrointestinal disorders.

Furthermore, a number of rising initiatives in pharmaceutical research and development were observed by the major players for the development of organoids and the application of organoids to different indications, such as lung cancer, genetic abnormalities, chronic kidney disease, cardiovascular disorders, and colon cancer, among others. These initiatives are also fueling the demand for organoids in the research field. For instance, according to ClinicalTrials.gov, a total of 79 clinical studies are there for organoids till 31st December 2022. Apart from that, the latest technological advancements in the development of organoids models were further improving the outcomes of organoids in pharmaceutical research. For instance, in October 2022, AIM Biotech Pte. Ltd. introduced organiX System. This system is capable of adding vascularization and immune competence to organoids which can improve the shelf life of organoids during the research procedure.

Thus, the above-mentioned factors are attributed to the growing demand and adoption of organoids in the pharmaceutical research field and have been instrumental in the market's growth. However, certain clinical disadvantages, including functional disparities between the organoids and actual organs, are limiting the adoption rate of organoids during the study period.

Organoids Market Trends

Drug Discovery & Personalized Medicine Segment Expected to Contribute a Significant Proportion in the Market

Based on product type, the drug discovery & personalized medicine segment is anticipated to hold a significant market share during the study period. The increasing prevalence of chronic disease, along with rising initiatives by the major players to introduce blockbuster drugs in the market, is the primary reason attributed to the higher adoption of advanced technology, such as organoids, for drug discovery. For instance, in August 2022, Bayer AG introduced finerenone for the treatment of chronic kidney disease. Further, in a research study published by the National Center for Biotechnology Information (NCBI) in May 2022, it was reported that patient-derived pancreatic cancer organoids proved to be efficient in drug discovery for pancreatic cancer.

Along with that, the rising trend for personalized medicine is also fueling the adoption rate of organoids in the research industry. For instance, according to an estimation by Personalized Medicine Coalition, a total of 300 personalized medicine were there in the market in the United States till 2022. Also, according to another report by Personalized Medicine Coalition, it was reported that approximately 35% of the total drug approval by the Food and Drug Administration (FDA) is for personalized medicine in 2021. Additionally, according to a report by Alix Venture in 2021, owing to certain factors, including traceability and potential to capture patient and tumor type diversity, organoids are increasingly used to study personalized medicines, thus supporting the demand and adoption of organoids in the development of personalized medicine. Additionally, certain clinical benefits, including the potential for capturing patient and tumor type diversity and conservation of cellular composition, among others, are fostering the adoption rate of organoids in the research for personalized medicine. For instance, according to ClinicalTrial.gov, 31 clinical trials based on patient-derived organoids were reported till 31st December 2022.

Thus, owing to the above-mentioned factors, the drug discovery & personalized medicine segment is anticipated to capture a significant market share during the study period.

North America Contributed to the Largest Market Share During the Forecast Period

North America region is anticipated to hold a dominant position in the global organoids market during the study period. The large patient population suffering from chronic diseases, advanced healthcare facilities, the presence of key players in the region, and rising R&D expenditure by the Federal Government in the region are the driving factors for the growth of the market in this region. According to data from the Centers for Disease Control and Prevention (CDC), it was reported that a total of 20.1 million adults of age 20 years and older in the United States have Coronary Artery Disease in 2022. Also, according to American Liver Foundation, the estimated number of new cases of liver cancer was 42,230 in the United States in 2021. Furthermore, according to an estimation published by National Center for Biotechnology Information in May 2022, it was reported that there were around 233,900 new cancer cases reported in Canada in 2022. Moreover, several clinical trials have been reported for a number of chronic diseases involving organoids in this region. According to ClinicalTrial.gov, a study titled "Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer" was started on August 2018 in Texas, United States and is anticipated to complete in December 2024. This study aims to establish a biobank of patient-derived organoids for the treatment of lung cancer and examine the ex-vivo responses of the potential organoids to a number of chemotherapeutic agents. These above-mentioned factors collectively foster the demand and adoption of organoids in healthcare research in North America.

Moreover, rising healthcare R&D funding in North America is bolstering the introduction of advanced technology in the research field. According to a research report by the U.S. Government Accountability Office (GAO) in December 2022, the federal government of the United States increased funding for research and development for the Department of Health and Human Services from USD 60.0 billion in 2020 to USD 68.8 billion in 2021. Thus, the upgradation of research methodologies in the medical field fosters new and advanced equipment, such as organoids, for precise research results and results in the market's growth.

Additionally, ongoing regulations and the modernization act by the government of the United States is limiting the use of animal testing in the clinical trials of drugs. This results in adopting an alternative way of testing drugs during clinical trials and other drug development procedures. Thus the adoption rate of organoids in the research procedure is increasing. For instance, the FDA Modernization Act of 2022 would eliminate the necessity of animal testing for the development of any human drugs.

Thus, due to the above-mentioned factors, the organoids market is expected to witness consistent growth in North America over the forecast period.

Organoids Industry Overview

The Organoids Market is consolidated and consists of a few major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies among them are Cellesce Ltd, Merck KGaA, 3Dnamics Inc., R&D Systems, Inc., Hubrecht Organoid Technology, Definigen, Known Medicine, and Dynomics Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Increasing Number of Research and Development Activity
  • 4.2.2 Latest Advancement in Organoids
• 4.3 Market Restraints
  • 4.3.1 Certain Charecteristics Differentiation with the Actual Organs
• 4.4 Porter's Five Force Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

• 5.1 By Product Type
  • 5.1.1 Intestine
  • 5.1.2 Liver
  • 5.1.3 Stomach
  • 5.1.4 Pancrease
  • 5.1.5 Others
• 5.2 By Application
  • 5.2.1 Drug Discovery and Personalized Medicine
  • 5.2.2 Drug Toxicity and Efficacy Testing
  • 5.2.3 Regenerative Medicine
  • 5.2.4 Developmental Biology
  • 5.2.5 Others
• 5.3 By End User
  • 5.3.1 Pharmaceutical and Biotechnology Companies
  • 5.3.2 Contract Research Organisations
  • 5.3.3 Research Institutes
• 5.4 Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle-East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Merck KGaA
  • 6.1.2 Cellesce Ltd
  • 6.1.3 3Dnamics Inc.
  • 6.1.4 R&D Systems, Inc.
  • 6.1.5 Hubrecht Organoid Technology
  • 6.1.6 Definigen
  • 6.1.7 Known Medicine
  • 6.1.8 Dynomics Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS